

| | |
|-----------------------------|--|
| Title | Plantaricyclin A, a novel circular bacteriocin produced by <i>Lactobacillus plantarum</i> NI326: purification, characterization, and heterologous production |
| Authors | Borrero, Juan; Kelly, Eoin; O'Connor, Paula M.; Kelleher, Philip; Scully, Colm; Cotter, Paul D.; Mahony, Jennifer; van Sinderen, Douwe |
| Publication date | 2017-12-15 |
| Original Citation | Borrero, J., Kelly, E., O'Connor, P. M., Kelleher, P., Scully, C., Cotter, P. D., Mahony, J. and van Sinderen, D. (2017) 'Plantaricyclin A, a novel circular bacteriocin produced by <i>Lactobacillus plantarum</i> NI326: purification, characterization, and heterologous production', <i>Applied and Environmental Microbiology</i> , 84(1), e01801-17 (10pp). doi:10.1128/aem.01801-17 |
| Type of publication | Article (peer-reviewed) |
| Link to publisher's version | 10.1128/aem.01801-17 |
| Rights | © 2017, American Society for Microbiology. All Rights Reserved. |
| Download date | 2023-05-05 18:58:39 |
| Item downloaded from | http://hdl.handle.net/10468/7134 |

1 **Purification, characterization and heterologous production of plantaricyclin**
2 **A, a novel circular bacteriocin produced by *Lactobacillus plantarum* NI326**

3

4 Juan Borrero^a, Eoin Kelly^a, Paula M. O'Connor^{b,c}, Philip Kelleher^a, Colm Scully^d, Paul D.
5 Cotter^{b,c}, Jennifer Mahony^{a,c} and Douwe van Sinderen^{a,c}.

6

7 School of Microbiology, University College Cork, Cork, Ireland ^a; Teagasc Food Research
8 Centre, Moorepark, Fermoy, Cork, Ireland ^b; APC Microbiome Institute, University College
9 Cork, Cork, Ireland ^c; Coca Cola Company, Brussels^d

10

11

12 **Running title:** Plantaricyclin A, a novel circular bacteriocin from *Lb. plantarum*

13

14 **Key words:** circular bacteriocin, *Alicyclobacillus acidoterrestris*, *Lactobacillus plantarum*,
15 immunity.

16

17 **ABSTRACT**

18 Bacteriocins from lactic acid bacteria (LAB) are of increasing interest in recent years due to
19 their potential as natural preservatives against food and beverage spoilage microorganisms. In
20 a screening study for LAB, we isolated a strain, *Lactobacillus plantarum* NI326, from olives
21 with activity against a strain belonging to the beverage-spoilage bacterium *Alicyclobacillus*
22 *acidoterrestris* spp. Genome sequencing of the strain enabled the identification of a gene
23 cluster encoding a putative circular bacteriocin and proteins involved in its modification,
24 transport and immunity. This novel bacteriocin, named plantaricyclin A (PlcA), was grouped
25 into the circular bacteriocin subgroup II due to its high degree of similarity with other
26 gassericin A-like bacteriocins. Purification of the supernatant of *Lb. plantarum* NI326 resulted
27 in an active peptide with a molecular mass of 5,570 Da, corresponding to that predicted from
28 the (processed) PlcA amino acid sequence. The Plc gene cluster was subsequently cloned and
29 expressed in *L. lactis* NZ9000, resulting in the production of an active 5,570 Da bacteriocin in
30 the supernatant. PlcA is produced as a 91-amino acid precursor with a 33 amino acid leader
31 peptide. This leader peptide is predicted to be removed, after which the N- and C-termini are
32 joined *via* a covalent linkage to form the mature 58 amino acid circular bacteriocin PlcA. This
33 is the first report of a characterized circular bacteriocin produced by *Lb. plantarum* and the
34 inhibition displayed against *A. acidoterrestris* sp1 highlights the potential use of this
35 bacteriocin as a preservative in food and beverages.

36
37 **IMPORTANCE**

38 In this work we describe the purification and characterization of a new antimicrobial peptide,
39 termed Plantaricyclin A (PlcA), produced by a *Lactobacillus plantarum* strain isolated from
40 olives. This peptide has a circular structure, and all the genes involved in its production,
41 circularization and secretion have been identified. PlcA shows antimicrobial activity against

42 different strains, including *Alicyclobacillus acidoterrestris*, a common beverage spoilage
43 bacteria causing important economic losses in the beverage industry every year. PlcA is the
44 first circular antimicrobial peptide described from *Lactobacillus plantarum*.
45

46 INTRODUCTION

47 Bacteriocins are ribosomally synthesized antimicrobial peptides produced by bacteria to
48 inhibit the growth of other, often closely related, strains. Bacteriocin production is a common
49 feature among food-grade lactic acid bacteria (LAB), and bacteriocins have, for this reason,
50 attracted considerable interest for their potential use as natural and non-toxic food
51 preservatives (1, 2). Some of these peptides have demonstrated greater efficacy than
52 conventional antibiotics against numerous pathogenic and drug-resistant bacteria, while
53 displaying no toxicity toward eukaryotic cells (3). For this reason, bacteriocins may also be
54 useful in human and veterinary applications as a powerful weapon in the ongoing battle
55 against antibiotic resistance, and for the treatment of local and systemic bacterial infections (3-
56 5).

57

58 A recent classification of bacteriocins of LAB established three main groups of these peptides
59 (6). Class I and class II are represented by heat-stable bacteriocins (<10 kDa), while class III
60 includes the thermo-labile bacteriocins (>10 kDa). Class I encompasses bacteriocins that
61 undergo enzymatic modification during biosynthesis, and this class is further subdivided into
62 six subclasses: lantiopeptides, circular bacteriocins, sactibiotics, linear azol(in)e-containing
63 peptides (LAPs), glycocins and lasso peptides. Class II bacteriocins include unmodified
64 bacteriocins, and this group is subdivided into four subclasses: pediocin-like, two-peptide,
65 leaderless and non-pediocin-like single-peptide bacteriocins. Class III includes (heat-sensitive)
66 unmodified bacteriocins larger than 10 kDa with a bacteriolytic or non-lytic mechanism of
67 action. This group can be further subdivided into two classes: the bacteriolysins and the non-
68 lytic bacteriocins.

69

70 Class Ib or circular bacteriocins constitute a unique family of active proteins in which the N-
71 and C-terminal ends are covalently linked to form a circular backbone. This additional bond is
72 thought to enhance the thermodynamic stability and structural integrity of the peptide and
73 consequently improve its biological activity (7-9). To date, only a small number of circular
74 bacteriocins have been described. These can be subdivided in two major groups according to
75 their physicochemical characteristics and level of sequence identity (9). Subgroup I
76 encompasses circular bacteriocins with a high content of positively charged amino acids and a
77 high isoelectric point (pI of ~10). This includes the most studied circular bacteriocin, enterocin
78 AS-48 (10), together with other bacteriocins such as carnocyclin A (11), circularin A (12),
79 lactocyclin Q (13), and garvicin ML (14). Subgroup II circular bacteriocins include
80 bacteriocins with a smaller number of positively charged amino acid residues and a medium to
81 low isoelectric point (pI between ~ 4 and 7). Currently this group comprises just three
82 members, gassericin A (15), butyrivibriocin AR10 (16) and acidocin B (17). However there is
83 an absence of consensus regarding the classification of circular bacteriocins, as some authors
84 consider that they should be grouped as Class II bacteriocins, instead of Class I (1).

85

86 In this study we screened 50 colonies, isolated from olives, for their potential to inhibit growth
87 of the beverage-spoilage strain *Alicyclobacillus acidoterrestris* sp1. We report the purification
88 and genetic characterization of a novel circular gassericin A-like bacteriocin, termed
89 plantaricyclin A produced by *Lactobacillus plantarum* NI326, with antimicrobial activity
90 against various microorganisms including *A. acidoterrestris* sp1.

91

92

93 MATERIALS AND METHODS

94

95 Cultures and growth conditions

96 The strains used in this study are summarized in Table 1. All *Lactobacillus*, *Pediococcus* and
97 *Leuconostoc* strains were grown in MRS (Oxoid, Hampshire, U.K.) at 30 °C, *A.*
98 *acidoterrestris* sp1 was grown in BAT broth (Pronadisa, Spain) at 45°C, while some of the
99 other indicator strains were grown in LB broth (1 % Peptone, 1 % NaCl, 0.5 % Yeast extract)
100 at 37 °C (*Escherichia coli*, *Salmonella typhimurium* and *Klebsiella pneumoniae*), BHI broth
101 (Oxoid) at 37 °C (*Staphylococcus aureus*, *Listeria monocytogenes*, *Listeria innocua* and
102 *Bacillus cereus*), TSB broth (Oxoid) at 37°C (*Streptococcus uberis* and *Streptococcus*
103 *dysgalactiae*) and M17 broth (Oxoid) supplemented with 0.5 % glucose (Sigma-Aldrich,
104 USA) at 30 °C (*Lactococcus lactis*) or at 37 °C (*Enterococcus faecium*). Chloramphenicol
105 (Sigma-Aldrich) was added at 5 µg/ml where required. All microorganisms were grown under
106 aerobic conditions. All strains were stored at -80 °C in their respective media with 20 %
107 glycerol until required.

108

109 Isolation of LAB strains from olives

110 Over 50 isolates were isolated from olives as previously described (18). Briefly, 5 g olives
111 were homogenised with 45 ml Ringers solution using a stomacher at 300 bpm for 1 min
112 (Stomacher circular 400, Seward, UK). Homogenate was serially diluted in Ringers solution,
113 and 100 µl of each dilution plated on MRS agar (Oxoid) plates supplemented with 100 µg/mL
114 cycloheximide (Sigma) to suppress fungal growth. Plates were then incubated at 30 °C
115 anaerobically for 2 days. Colonies obtained were handpicked and inoculated into 250 µl
116 aliquots of MRS broth in 96 well plates. Cultures were grown anaerobically overnight at 30 °C
117 and stored at -80 °C with 20 % glycerol for further analysis.

118

119 **Isolation of anti-*A. acidoterrestris* sp1 bacteriocin-producing LAB**

120 LABs exerting antimicrobial activity were identified using the spot-on-lawn method (18).
121 Briefly, 5 µl aliquots of LAB cultures were spotted onto MRS agar plates and grown at 30 °C
122 anaerobically for 48 h. Plates were then overlaid with 5 mL of MRS soft agar (MRS broth
123 supplemented with 0.8 % bacteriological agar) seeded with $10^5 - 10^6$ CFU/mL of an overnight
124 culture of *L. lactis* HP. Plates were incubated at 30 °C for 48 h after which zones of inhibition
125 surrounding the LAB colony were measured.

126 The LAB isolate showing inhibition against *L. lactis* HP was further cultured in 10 ml MRS
127 broth and grown at 30 °C overnight. Cell-free culture supernatant (CFS) was obtained by
128 centrifugation of the culture at 12,000 g, 4 °C for 10 min and filtered through 0.2 µm pore-size
129 filters (Whatman Int. Ltd., Maidstone, UK). The activity of the CFS against *A. acidoterrestris*
130 sp1 was analysed using an agar diffusion test (ADT) (19). Briefly, 100 µl aliquots of CFS were
131 placed in wells (6-mm diameter) bored in cooled Alicyclobacillus agar (Pronadisa) plates (30
132 ml) previously seeded (10^5 CFU/ml) with *A. acidoterrestris* sp1. Plates were incubated at 50
133 °C to allow growth of the target organism and checked for zones of inhibition after 24-48 h.

134

135 **Identification of LAB isolates**

136 Individual colonies were used as templates for PCR. The primers Luc-F (5' CTT GTT ACG
137 ACT TCA CCC 3') and Luc-R (5' TGC CTA ATA CAT GCA AGT 3') (Eurofins MWG,
138 Ebersberg, Germany) were used to amplify a variable region of the 16S rRNA gene (20). The
139 following conditions were used for the PCR reactions: 95 °C for 60 s, 53 °C for 60 s, and 72
140 °C for 95 s, for 30 cycles. The DNA from individually purified amplicons was subjected to
141 Sanger sequencing (Eurofins MWG) and the corresponding species identity was obtained by
142 comparative sequence analysis (BLASTN) against available sequence data in the National

143 Center for Biotechnology Information (NCBI) database (<http://www.ncbi.nlm.nih.gov/>
144 BLAST).

145

146 ***Lactobacillus. plantarum* NI326 genome sequencing, genome annotation and bacteriocin**
147 **screening**

148 The genome of *Lb. plantarum* NI326 was sequenced using a combined Roche GS-FLX
149 Titanium and Illumina HiSeq 2000 approach (GATC Biotech, Konstanz, Germany), to a final
150 coverage of ~490-fold. Sequences obtained were first quality checked using IlluQC.pl from
151 the NGS QC Toolkit (v2.3) (<http://www.nipgr.res.in/ngsqctoolkit.html>) (21) and assembled
152 with AbySS (v1.9.0) (22).

153 Following sequence assembly, the generated contigs were employed to perform Open Reading
154 Frame (ORF) prediction with Prodigal v2.5 prediction software (<http://prodigal.ornl.gov/>),
155 supported by BLASTX v2.2.26 alignments (23). ORFs were automatically annotated using
156 BLASTP v2.2.26 (23) analysis against the non-redundant protein databases curated by the
157 NCBI Database. Following automatic annotation, ORFs were manually curated using Artemis
158 v16 genome browser and annotation tool (<http://www.sanger.ac.uk/science/tools/artemis>). The
159 software tool was used to inspect and validate ORF results, to adjust start codons where
160 necessary, and to aid in the identification of pseudogenes. The resulting ORF annotations were
161 further refined, where required, using alternative databases; Pfam (24) and Uniprot/EMBL
162 (<http://www.uniprot.org/>). Transfer tRNA was predicted using tRNA-scan-SE v1.4 (25). The
163 whole genome was analysed with the web-based bacteriocin genome mining tool BAGEL3
164 (<http://bagel.molgenrug.nl/>) (26) to search for known and/or potential novel bacteriocins.

165

166 **Accession numbers**

167 The GenBank accession number provided for the nucleotide sequence reported in this study is
168 NDXC000000000.

169

170 **Molecular cloning of *plc* gene cluster, *plcD* and *plcI* into pNZ8048 and transformation in**
171 ***L. lactis* NZ9000**

172 The primers, PCR fragments and plasmids used in this study are listed in Table 2. All primers
173 were ordered from Eurofins MWG. Plasmid derivatives were constructed as follows: primers
174 Plc-F/Plc-R were used for PCR-amplification of a 3,172-bp fragment from total genomic DNA
175 of *Lb. plantarum* NI326, which encompassed the entire *plc* gene cluster including its
176 promoter(s). Using this *plc* gene cluster fragment as template and the primer pairs NcoI-
177 Plc/XbaI-Plc, NcoI-PlcD/XbaI-PlcD, NcoI-PlcI/XbaI-PlcI and NcoI-PlcD/XbaI-PlcI,
178 fragments encompassing *plcADITEB*, *plcD*, *plcI* and *plcDI*, respectively, were amplified
179 (Table 3). Such fragments were digested with *NcoI* and *XbaI* and ligated into pNZ8048,
180 digested with the same enzymes. The ligation mixtures were used to transform *L. lactis*
181 NZ9000 competent cells as previously described (27). The plasmid derivatives pNZPlc,
182 pNZPlcD, pNZPlcI and pNZPlcDI, were checked by colony-PCR and sequencing of the
183 inserts using primers PNZ-F/PNZ-R.

184

185 **Purification and MALDI TOF mass spectrometry analysis of PlcA**

186 PlcA was purified from *Lb. plantarum* NI326 and *L. lactis* NZ9000 transformed with pNZPlc,
187 as described previously (28) with modifications. Briefly, a 1 L CFS of *Lb. plantarum* NI326
188 was obtained as previously described. Recombinant *L. lactis* NZ9000 – pNZPlc was induced
189 for the production of PlcA at an optical density at 600 nm (OD₆₀₀) of 0.5, using nisin A
190 (Nisaplin, Dupont, USA) at a final concentration of 10 ng/ml. The induced culture was grown
191 at 32 °C for 3 h. CFS was obtained by centrifugation of the culture at 12,000 × *g* at 4 °C for 10

192 min. Activity of the CFS from either strain against *A. acidoterrestris* sp1 was confirmed on an
193 ADT as previously described. CFS was applied to a 10g (60 ml) Varian C-18 Bond Elution
194 Column (Varian, Harbor City, CA) pre-equilibrated with methanol and water. The column was
195 washed with 20 % ethanol and the inhibitory activity was eluted in 100 mls of 70 % 2-
196 propanol 0.1 % TFA. 15 ml aliquots were concentrated to 2 ml through the removal of 2-
197 propanol by rotary evaporation (Buchi). Samples were then applied to a semi preparative
198 Vydac C4 Mass Spec (10 x 250 mm, 300Å, 5µ) RP-HPLC column (Grace, Columbia, USA)
199 running an acetonitrile and propan-2-ol gradient described as follows: 5-55 % buffer B and 0-5
200 % buffer C over 25 minutes followed by and 55-19 % buffer B and 5-65 % buffer C over 60
201 minutes, 19-5 % buffer B and 65-95 % buffer C over 5 minutes where buffer A is Milli Q
202 water containing 0.1 % TFA, buffer B is 90 % acetonitrile 0.1 % TFA and buffer C is 90 %
203 propan-2-ol 0.1 % TFA. Eluent was monitored at 214 nm and fractions were collected at 1
204 minute intervals. Fractions were assayed on *Lactobacillus bulgaricus* indicator plates and
205 active fractions assayed for the antimicrobial mass of interest using MALDI TOF mass
206 spectrometry (MALDI TOF MS). MALDI TOF MS was performed with an Axima TOF²
207 MALDI TOF mass spectrometer (Shimadzu Biotech, Manchester, UK) as described by Field
208 et al (28).

209

210 **Analysis of Immunity against PlcA**

211 The immunity of wild type *L. lactis* NZ9000 and recombinant strains *L. lactis* NZ9000 –
212 pNZPlcD, *L. lactis* NZ9000 – pNZPlcI and *L. lactis* NZ9000 – pNZPlcDI was tested against
213 CFS from *Lb. plantarum* NI326 on an ADT assay as above described. The indicator strains
214 were seeded in GM17 – 0.8 % agar with and without 10 ng/ml Nisin A. The area of zones of
215 inhibition was measured after 24 hours growth at 30 °C. The absence of a zone indicates that
216 the strain is immune to PlcA.

217

218 Sensitivity of PlcA to heat, pH and proteolytic enzymes

219 Aliquots of PlcA-containing fraction obtained following Reversed Phase HPLC were
220 subjected to the following treatments: (i) 20-fold (v/v) dilution with 30 % 2-propanol
221 containing 0.1 % TFA and heating at 80 °C and 100 °C for 30 min and at 121 °C for 15 min to
222 determine the stability of PlcA to heat; (ii) 20-fold (v/v) dilution in 10 mM Tris buffer
223 followed by pH adjustment at 2, 3, 4, 5, 6, 7, 8, 9 and 10 with 1 M HCl or 1 M NaOH to
224 evaluate the effect of pH on bacteriocin activity; and (iii) dilution as in (ii) followed by the
225 addition of α -chymotrypsin (Sigma), pepsin (Sigma), pronase (Sigma) and proteinase K
226 (Sigma) at pH 7.0. Each enzyme was added to a final concentration of 1 mg/ml, to determine
227 PlcA sensitivity to proteolytic enzymes. After each treatment, the residual antimicrobial
228 activity of PlcA was determined by the agar diffusion test (ADT) with *A. acidoterrestris* sp1 as
229 the indicator microorganism.

230

231 Antimicrobial spectrum of PlcA

232 Aliquots of PlcA were used to test its antimicrobial activity against various indicators (Table
233 1) using an ADT assay as described above.

234

235

236 RESULTS AND DISCUSSION

237
238 *Alicyclobacillus acidoterrestris* is considered to be one of the species with the highest food
239 spoilage impact worldwide (29). They are thermo-acidophilic spore-forming bacteria with a
240 strong spoiling potential especially in low pH juices. The presence of *A. acidoterrestris* in
241 juices is difficult to detect visually, but its presence is associated with an unpleasant odour
242 caused by the production of guaiacol and other halophenols by the strain. Bacteriocins, such as
243 the lantibiotic nisin A or the circular bacteriocin enterocin AS-48, have shown some promising
244 results as strategies to inhibit growth of *A. acidoterrestris* in juices (30, 31).

245

246 Isolation and identification of *Lactobacillus plantarum* NI326.

247 In this study we screened a number of isolates of LAB from olives with the aim of selecting
248 those showing antimicrobial activity against *A. acidoterrestris* sp1. 50 potential LAB isolates
249 were obtained from the olive homogenate plated on MRS plates. Single colonies were streaked
250 onto fresh MRS plates and overlaid with *L. lactis* HP. Only one out of the 50 tested colonies
251 exhibited a zone of inhibition against the indicator strain. A CFS of this strain produced an
252 inhibitory zone against *A. acidoterrestris* sp1 on an ADT, confirming that this isolate produces
253 an extracellular antimicrobial compound against *A. acidoterrestris* sp1. This colony was
254 identified as *Lb. plantarum* by 16S rDNA sequencing and designated *Lb. plantarum* NI326.
255 No zone of inhibition was apparent when the CFS was first treated with proteinase K
256 confirming the proteinaceous nature of the antimicrobial compound (data not shown).

257

258 Genome sequence analysis and annotation bacteriocin encoding gene cluster of *Lb.* 259 *plantarum* NI326.

260 To find potential bacteriocin-encoding gene clusters, the entire genome of *Lb. plantarum*
261 NI326 was sequenced generating 84 contigs following sequence assembly. *In silico* analysis of

the 84 contigs with BAGEL3 detected a potential bacteriocin gene cluster predicted to encode a peptide with a 43-AA putative conserved domain corresponding to the class Ib-subgroup II gassericin A-like circular bacteriocins. This putative peptide, designated here as plantaricyclin A (PlcA), exhibits 67 % similarity to the circular bacteriocin gassericin A. An alignment of this peptide with the other members of the gassericin A-like circular bacteriocin group: gassericin A (GaaA), acidocin B (AciB) and butyrivibriocin AR10 (BviA), revealed a high degree of similarity with PlcA facilitated the prediction of the potential cleavage site of the signal peptide from the mature peptide to be between amino acids N33 and I34 (Figure 1). Both GaaA and AciB are synthesized as 91 AA pre-peptides with 33 AA leader peptides that are cleaved off, followed by a covalent linkage between the N- and C-terminus, to form the mature 58 amino acid circular bacteriocin. In previous studies, sequence alignments between characterized and hypothetical subgroup II circular bacteriocins has revealed the presence of a fully conserved asparaginyl cleavage site (17), which is also present in PlcA.

The function of these leader peptides and mechanism through which peptide circularization occurs is still unclear. One of the biggest challenges in the field of circular proteins is finding out how their ends are stitched together from their linear precursors (32). Identification of the mechanism involved has the potential to facilitate the creation of new, highly stable antimicrobial agents for use in food, veterinary and medical applications (11). PlcA has a predicted mass of 5,588 Da and represents a new bacteriocin within the Class Ib Subgroup II and the first (predicted) circular bacteriocin isolated from *Lb. plantarum*.

Analysis of the PlcA gene cluster revealed the presence of seven ORFs downstream of the PlcA-encoding gene (*plcA*), with sequence and organisational similarity to those found in the gene clusters responsible for GaaA and AciB production (Figure 2). Accordingly, *plcA* is

287 followed by *plcD*, which encodes a putative 157 AA membrane associated protein with a
288 DUF95 conserved domain. Recent research suggests that DUF95 proteins play a dual role in
289 the biosynthesis of circular peptides, as an immunity-associated transporter protein and as a
290 secretion-aiding agent (33). ORF *plcI* is immediately downstream of *plcD*, and encodes a 54
291 AA protein with a hypothetical function as an immunity protein. Kawai et al (34) showed that
292 heterologous expression of GaaI in *Lactococcus lactis* confers a 7-fold higher resistance to
293 gassericin A compared to a control strain.

294

295 The next two genes of the cluster (*plcE* and *plcT*) encode proteins of 227 AA and 214 AA,
296 respectively. Both have conserved ATP-binding domains linked to proteins of the ABC
297 transporter family and based on homology to their equivalents from GaaA and AciB clusters,
298 they are most likely involved in the secretion of PlcA. The downstream *plcB* and *plcC* genes
299 are located in positions that are different from their homologs in the clusters for GaaA and
300 AciB production (Figure 2). The function of the proteins coded by these two genes is still
301 unknown, but their presence in all of the clusters from circular bacteriocins clearly indicates
302 that they must play an important role (8).

303

304 **Heterologous production of PlcA in *L. lactis* NZ9000**

305 To further confirm that PlcA is responsible for the activity shown by *Lb. plantarum* NI326, the
306 entire *plc* cluster was cloned into the nisin-inducible plasmid pNZ8048 (pNZPlc) and
307 transformed into *L. lactis* NZ9000, a naturally non-bacteriocin producing strain. The CFS from
308 *L. lactis* pNZPlc exhibited antimicrobial activity against *A. acidoterrestris* sp1 similar to that
309 from the wildtype *Lb. plantarum* NI326 (Figure 3a). The production of PlcA by *L. lactis*
310 confirms that the cluster contains all the information necessary for the correct production,
311 modification and secretion of PlcA. Based on these results and the similarity of the *plc* cluster

312 to those from GaaA and AciB, we can hypothesize that the biosynthetic machinery for all
313 members of this bacteriocin subgroup is similar.

314

315 **Analysis of immunity to PlcA**

316 In order to determine if *plcD* and/or *plcI* code immunity proteins for PlcA, the genes were
317 cloned individually or together in the NisA-inducible vector pNZ8048 and transformed into *L.*
318 *lactis* NZ9000. The recombinant strain *L. lactis* NZ9000 – pNZPlcDI induced with nisin A
319 displayed full resistance to PlcA while strains *L. lactis* NZ9000 – pNZPlcD and *L. lactis*
320 NZ9000 – pNZPlcI induced with nisA showed 86 % and 62 % sensitivity against PlcA,
321 respectively, in comparison to the activity of the bacteriocin against the control strain *L. lactis*
322 NZ9000 – pNZ8048 (Figure 3b). Therefore, although both proteins individually appeared to
323 confer partial immunity to *L. lactis* NZ9000 against the antimicrobial activity of PlcA, the
324 recombinant strain was fully protected against the action of PlcA when both proteins were
325 being produced concomitantly. Similar results have been observed with other circular
326 bacteriocins such as carnocyclin A, where the production of the immunity protein (CclI) was
327 not enough to confer full protection to the producer and only when CclD and CclI were co-
328 produced did the strain show full immunity (35).

329

330 **Purification and MALDI TOF analyses of the antimicrobial activity of *Lb. plantarum***

331 **NI326**

332 The antimicrobial peptide produced by *Lb. plantarum* NI326 and *L. lactis* pNZPlc CFS was
333 purified by Reversed Phase-HPLC and the molecular mass analyzed by MALDI TOF MS. In
334 both cases a single mass of 5,572 Da was detected in the active fractions (Figure 4). The 18 Da
335 difference between the molecular mass of PlcA and its theoretical mass calculated from the

336 AA sequence corresponds to the loss of a molecule of water that occurs during circularization
337 of the peptide as reported for other circular bacteriocins (17, 36).

338

339 **Sensitivity of plantaricyclin A to heat, pH and proteolytic enzymes.**

340 The antimicrobial activity of partially purified PlcA was the same as the initial antagonistic
341 activity following exposure to temperatures ranging from 30 °C to 100 °C for 10 min,
342 suggesting the relative stability of the bacteriocin.. No antimicrobial activity was lost when
343 PlcA was adjusted to pH values 2 to 10. The antimicrobial activity of PlcA was completely
344 lost when treated with proteinase K and pronase, whereas pepsin, and α -chymotrypsin
345 treatments resulted in the retention of 100 % and 78 % of the initial antagonistic antimicrobial
346 activity, respectively (results not shown).

347 The resistance of circular bacteriocins to temperature, pH variations and proteolytic enzymes
348 is mainly due to their three-dimensional conformation. The solution structure of acidocin B
349 has recently been solved. Accordingly, AciB is composed of four α -helices of similar length
350 folded to form a compact, globular bundle that allow the formation of a central pore,
351 resembling the structure of the saposins. The surface of acidocin B and gassericin A is
352 dominated by hydrophobic and uncharged residues and, therefore, it is believed that the initial
353 contact between these circular peptides and the target strains is mediated by hydrophobic
354 interactions (17).

355

356 **Antimicrobial spectrum of plantaricyclin A.**

357 Aliquots of the HPLC purified fractions of PlcA were evaluated for their antimicrobial activity
358 and inhibitory spectrum against different indicator microorganisms. Of these only *A.*
359 *acidoterrestris* sp1, *Lb. bulgaricus* UCC, *Pediococcus inopinatus* 1011 and all tested
360 lactococcal strains were inhibited by the bacteriocin produced by *Lb. plantarum* NI326 (Table

361 1). In comparison with other circular bacteriocins, PlcA possesses a narrow spectrum of
362 activity. The low yields obtained during the purification of PlcA may explain the lack of
363 activity against some of the indicators used.

364

365 In addition to the spectra of inhibition, we observed some other differences between PlcA and
366 the other members of subgroup II, such as a higher isoelectric point (8.6) and a net charge of
367 +1. In fact some authors use the pI values and net charges to differentiate between circular
368 bacteriocins of subgroup I (pI~10 and positively charged) from circular bacteriocins of
369 subgroup II (pI 4 to 7 and uncharged or slightly negative) (9). According to this classification
370 system PlcA should be placed in an intermediate position between subgroups I and II.
371 However, we strongly believe that this peptide should be classified within subgroup II and
372 propose to modify the classification criteria and broaden the pI range for this subgroup to be
373 between 4 to ~9.

374

375 The peptide plantaricyclin A is the first circular bacteriocin isolated and characterized from a
376 *Lb. plantarum* strain. The high level of antimicrobial activity observed against the food and
377 beverage spoilage microorganism *Alicyclobacillus acidoterrestris* is of great interest as this
378 strain represents a significant problem for the food industry. The use of bacteriocins, such as
379 nisin A and enterocin AS-48, as preservatives in low pH beverages and juices has shown some
380 promising results to control the growth of *A. acidoterrestris* (37). The circular nature of PlcA
381 makes it especially interesting for industrial applications as this peptide could survive and
382 retain most of the activity under changing conditions (temperature and pH, for example)
383 during food/beverage manufacture. Moreover, the narrow spectrum of activity from PlcA can
384 be considered as an advantage specially in fermented beverages. In comparison to other broad
385 spectrum bacteriocins such as nisin A or enterocin AS-48, PlcA could be used to specifically

386 target *A. acidoterrestris* spp while having little or no effect against other desirable
387 microorganisms present in the beverage.

388

389

ACKNOWLEDGEMENTS

390 This work was supported by a grant from Enterprise Ireland – Innovation Partnership
391 Programme IP/2013/0254. DvS is a member of the APC Microbiome Institute funded by
392 Science Foundation Ireland (SFI), through the Irish Government’s National Development Plan
393 (Grant number SFI/12/RC/2273). JM is the recipient of a Starting Investigator Research Grant
394 funded by SFI (Ref. No. 15/SIRG/3430).

395

396

REFERENCES

- 397 1. Cotter PD, Hill C, Ross RP. 2005. Bacteriocins: developing innate immunity for food.
398 Nat Rev Microbiol 3:777-88.
- 399 2. Galvez A, Abriouel H, Lopez RL, Ben Omar N. 2007. Bacteriocin-based strategies
400 for food biopreservation. Int J Food Microbiol 120:51-70.
- 401 3. Cotter PD, Ross RP, Hill C. 2013. Bacteriocins - a viable alternative to antibiotics?
402 Nat Rev Microbiol 11:95-105.
- 403 4. Sit CS, Vederas JC. 2008. Approaches to the discovery of new antibacterial agents
404 based on bacteriocins. Biochem Cell Biol 86:116-23.
- 405 5. Sang Y, Blecha F. 2008. Antimicrobial peptides and bacteriocins: alternatives to
406 traditional antibiotics. Anim Health Res Rev 9:227-35.
- 407 6. Alvarez-Sieiro P, Montalban-Lopez M, Mu D, Kuipers OP. 2016. Bacteriocins of
408 lactic acid bacteria: extending the family. Appl Microbiol Biotechnol 100:2939-51.
- 409 7. Gong X, Martin-Visscher LA, Nahirney D, Vederas JC, Duszyk M. 2009. The
410 circular bacteriocin, carnocyclin A, forms anion-selective channels in lipid bilayers.
411 Biochim Biophys Acta 1788:1797-803.
- 412 8. van Belkum MJ, Martin-Visscher LA, Vederas JC. 2011. Structure and genetics of
413 circular bacteriocins. Trends Microbiol 19:411-8.
- 414 9. Gabrielsen C, Brede DA, Nes IF, Diep DB. 2014. Circular bacteriocins: biosynthesis
415 and mode of action. Appl Environ Microbiol 80:6854-62.
- 416 10. Maqueda M, Galvez A, Bueno MM, Sanchez-Barrena MJ, Gonzalez C, Albert A,
417 Rico M, Valdivia E. 2004. Peptide AS-48: prototype of a new class of cyclic
418 bacteriocins. Curr Protein Pept Sci 5:399-416.
- 419 11. Martin-Visscher LA, van Belkum MJ, Garneau-Tsodikova S, Whittall RM, Zheng J,
420 McMullen LM, Vederas JC. 2008. Isolation and characterization of carnocyclin a, a
421 novel circular bacteriocin produced by *Carnobacterium maltaromaticum* UAL307.
422 Appl Environ Microbiol 74:4756-63.
- 423 12. Kemperman R, Jonker M, Nauta A, Kuipers OP, Kok J. 2003. Functional analysis of
424 the gene cluster involved in production of the bacteriocin circularin A by *Clostridium*
425 *beijerinckii* ATCC 25752. Appl Environ Microbiol 69:5839-48.
- 426 13. Sawa N, Zendo T, Kiyofuji J, Fujita K, Himeno K, Nakayama J, Sonomoto K. 2009.
427 Identification and characterization of lactocyclin Q, a novel cyclic bacteriocin
428 produced by *Lactococcus* sp. strain QU 12. Appl Environ Microbiol 75:1552-8.
- 429 14. Borrero J, Brede DA, Skaugen M, Diep DB, Herranz C, Nes IF, Cintas LM,
430 Hernandez PE. 2011. Characterization of garvicin ML, a novel circular bacteriocin
431 produced by *Lactococcus garvieae* DCC43, isolated from mallard ducks (*Anas*
432 *platyrhynchos*). Appl Environ Microbiol 77:369-73.
- 433 15. Kawai Y, Kemperman R, Kok J, Saito T. 2004. The circular bacteriocins gassericin A
434 and circularin A. Curr Protein Pept Sci 5:393-8.
- 435 16. Kalmokoff ML, Cyr TD, Hefford MA, Whitford MF, Teather RM. 2003.
436 Butyrivibriocin AR10, a new cyclic bacteriocin produced by the ruminal anaerobe
437 *Butyrivibrio fibrisolvens* AR10: characterization of the gene and peptide. Can J
438 Microbiol 49:763-73.
- 439 17. Acedo JZ, van Belkum MJ, Lohans CT, McKay RT, Miskolzie M, Vederas JC. 2015.
440 Solution structure of acidocin B, a circular bacteriocin produced by *Lactobacillus*
441 *acidophilus* M46. Appl Environ Microbiol 81:2910-8.
- 442 18. Crowley S, Mahony J, van Sinderen D. 2013. Broad-spectrum antifungal-producing
443 lactic acid bacteria and their application in fruit models. Folia Microbiol (Praha)
444 58:291-9.

- 445 19. Gutierrez J, Larsen R, Cintas LM, Kok J, Hernandez PE. 2006. High-level
446 heterologous production and functional expression of the sec-dependent enterocin P
447 from *Enterococcus faecium* P13 in *Lactococcus lactis*. *Appl Microbiol Biotechnol*
448 72:41-51.
- 449 20. Corsetti A, Settanni L, Van Sinderen D. 2004. Characterization of bacteriocin-like
450 inhibitory substances (BLIS) from sourdough lactic acid bacteria and evaluation of
451 their in vitro and in situ activity. *Journal of Applied Microbiology* 96:521-534.
- 452 21. Patel RK, Jain M. 2012. NGS QC Toolkit: a toolkit for quality control of next
453 generation sequencing data. *PLoS One* 7:e30619.
- 454 22. Simpson JT, Wong K, Jackman SD, Schein JE, Jones SJ, Birol I. 2009. ABySS: a
455 parallel assembler for short read sequence data. *Genome Res* 19:1117-23.
- 456 23. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. 1990. Basic local alignment
457 search tool. *J Mol Biol* 215:403-10.
- 458 24. Finn RD, Coghill P, Eberhardt RY, Eddy SR, Mistry J, Mitchell AL, Potter SC, Punta
459 M, Qureshi M, Sangrador-Vegas A, Salazar GA, Tate J, Bateman A. 2016. The Pfam
460 protein families database: towards a more sustainable future. *Nucleic Acids Res*
461 44:D279-85.
- 462 25. Schattner P, Brooks AN, Lowe TM. 2005. The tRNAscan-SE, snoscan and snoGPS
463 web servers for the detection of tRNAs and snoRNAs. *Nucleic Acids Res* 33:W686-9.
- 464 26. van Heel AJ, de Jong A, Montalban-Lopez M, Kok J, Kuipers OP. 2013. BAGEL3:
465 Automated identification of genes encoding bacteriocins and (non-)bactericidal
466 posttranslationally modified peptides. *Nucleic Acids Res* 41:W448-53.
- 467 27. Holo H, Nes IF. 1989. High-Frequency Transformation, by Electroporation, of
468 *Lactococcus lactis* subsp. *cremoris* Grown with Glycine in Osmotically Stabilized
469 Media. *Applied and Environmental Microbiology* 55:3119-3123.
- 470 28. Field D, Begley M, O'Connor PM, Daly KM, Hugenholtz F, Cotter PD, Hill C, Ross
471 RP. 2012. Bioengineered Nisin A Derivatives with Enhanced Activity against Both
472 Gram Positive and Gram Negative Pathogens. *PLOS ONE* 7:e46884.
- 473 29. Bevilacqua A, Sinigaglia M, Corbo MR. 2008. *Alicyclobacillus acidoterrestris*: new
474 methods for inhibiting spore germination. *Int J Food Microbiol* 125:103-10.
- 475 30. Yamazaki K, Murakami M, Kawai Y, Inoue N, Matsuda T. 2000. Use of nisin for
476 inhibition of *Alicyclobacillus acidoterrestris* in acidic drinks. *Food Microbiology*
477 17:315-320.
- 478 31. Grande MJ, Lucas R, Abriouel H, Omar NB, Maqueda M, Martínez-Bueno M,
479 Martínez-Cañamero M, Valdivia E, Gálvez A. 2005. Control of *Alicyclobacillus*
480 *acidoterrestris* in fruit juices by enterocin AS-48. *International Journal of Food*
481 *Microbiology* 104:289-297.
- 482 32. Craik DJ. 2006. Chemistry. Seamless proteins tie up their loose ends. *Science*
483 311:1563-4.
- 484 33. Mu F, Masuda Y, Zendo T, Ono H, Kitagawa H, Ito H, Nakayama J, Sonomoto K.
485 2014. Biological function of a DUF95 superfamily protein involved in the
486 biosynthesis of a circular bacteriocin, leucocyclicin Q. *J Biosci Bioeng* 117:158-64.
- 487 34. Kawai Y, Kusnadi J, Kemperman R, Kok J, Ito Y, Endo M, Arakawa K, Uchida H,
488 Nishimura J, Kitazawa H, Saito T. 2009. DNA sequencing and homologous
489 expression of a small peptide conferring immunity to gassericin A, a circular
490 bacteriocin produced by *Lactobacillus gasseri* LA39. *Appl Environ Microbiol*
491 75:1324-30.
- 492 35. van Belkum MJ, Martin-Visscher LA, Vederas JC. 2010. Cloning and
493 Characterization of the Gene Cluster Involved in the Production of the Circular
494 Bacteriocin Carnocyclin A. *Probiotics and Antimicrobial Proteins* 2:218-225.

- 495 36. Martinez-Bueno M, Maqueda M, Galvez A, Samyn B, Van Beeumen J, Coyette J,
496 Valdivia E. 1994. Determination of the gene sequence and the molecular structure of
497 the enterococcal peptide antibiotic AS-48. *J Bacteriol* 176:6334-9.
- 498 37. Tianli Y, Jiangbo Z, Yahong Y. 2014. Spoilage by Alicyclobacillus Bacteria in Juice
499 and Beverage Products: Chemical, Physical, and Combined Control Methods.
500 *Comprehensive Reviews in Food Science and Food Safety* 13:771-797.
- 501 38. Kuipers OP, de Ruyter PGGA, Kleerebezem M, de Vos WM. 1998. Quorum sensing-
502 controlled gene expression in lactic acid bacteria. *Journal of Biotechnology* 64:15-21.
- 503 39. Edgar RC. 2004. MUSCLE: multiple sequence alignment with high accuracy and
504 high throughput. *Nucleic Acids Res* 32:1792-7.
- 505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544

545 Table 1. Strains used in this study, sources, and activity of PlcA (+: zone of inhibition
546 observed; - : no zone of inhibition observed).
547

| Strain | Source | Activity |
|---|-----------|----------|
| <i>Alicyclobacillus acidoterrestris</i> sp1 | Coca Cola | + |
| <i>Lactococcus lactis</i> HP | UCC | + |
| <i>Lactococcus lactis</i> KH | UCC | + |
| <i>Lactococcus lactis</i> MG1363 | UCC | + |
| <i>Lactococcus lactis</i> RT28 | UCC | + |
| <i>Lactococcus lactis</i> NZ9000 | UCC | + |
| <i>Lactobacillus bulgaricus</i> UCC | UCC | + |
| <i>Lactobacillus plantarum</i> -PARA | UCC | - |
| <i>Lactobacillus plantarum</i> WCFSI | UCC | - |
| <i>Lactobacillus brevis</i> MB124 | UCC | - |
| <i>Lactobacillus brevis</i> SAC12 | UCC | - |
| <i>Lactobacillus brevis</i> L102 | UCC | - |
| <i>Lactobacillus brevis</i> L94 | UCC | - |
| <i>Pediococcus claussenii</i> H5 | UCC | - |
| <i>Pediococcus inopinatus</i> 1011 | UCC | + |
| <i>Enterococcus faecium</i> DPC1146 | UCC | - |
| <i>Listeria innocua</i> UCC | UCC | - |
| <i>Listeria monocytogenes</i> EgDe | UCC | - |
| <i>Listeria monocytogenes</i> 33077 | UCC | - |
| <i>Escherichia coli</i> EC10B | UCC | - |
| <i>Staphylococcus aureus</i> DPC5243 | UCC | - |
| <i>Streptococcus uberis</i> ATCC700407 | UCC | - |
| <i>Streptococcus dysgalactiae</i> GrpC | UCC | - |
| <i>Salmonella typhimurium</i> UTC1lux | UCC | - |
| <i>Klebsiella pneumoniae</i> UCC | UCC | - |
| <i>Bacillus cereus</i> DPC6087 | UCC | - |

548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564

Table 2. Putative proteins derived from the *plca* operon

| ORF | Length (amino acids) | Amino acids identity (%) relative to gassericin A gene cluster homologs | Hypothetical function | Genbank accession no. |
|-------------|----------------------------|---|----------------------------|-----------------------------|
| <i>plcA</i> | 90 | 56 | Plantaricyclin A precursor | |
| <i>plcD</i> | 157 | 33 | Unknown, DUF95 family | |
| <i>plcI</i> | 54 | 33 | Immunity | |
| <i>plcT</i> | 227 | 45 | ATP-binding protein | |
| <i>plcE</i> | 214 | 37 | Membrane transporter | |
| <i>plcB</i> | 173 | 30 | Unknown | |
| <i>plcC</i> | 56 | 35 | Unknown | |

565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602

603
604
605
606


Table 3. Primers, PCR products and plasmids used in this study.

| Primer | Nucleotide sequence (5' - 3') ^a | PCR fragment |
|--------------|---|--------------|
| Plc-F | AACGCAAATGTTCCACACGG | Plc-Clust |
| Plc-R | GGATTGGACTAGTAGCTCTAGGGT | Plc-Clust |
| NcoI-Plc | CACTC <u>ACCATGGG</u> TTAATGCTTTTCAGCATATCGT AGTAAAT | PlcADITEB |
| XbaI-Plc | ATCTAT <u>CTAGACT</u> ATAAAAAAATCAAGCTATATA TAGG | PlcADITEB |
| NcoI-PlcD | CACTC <u>ACCATGGT</u> GAATAAACCGCGGAGTAATA TC | PlcD / PlcDI |
| XbaI-PlcD | ATCTAT <u>CTAGAT</u> TAATCTCCTAACAACCATAAGG C | PlcD |
| NcoI-PlcI | CACTC <u>ACCATGGT</u> TGTTAGGAGATTAATTATGAA GAATTTAG | PlcI |
| XbaI-PlcI | ATCTAT <u>CTAGAT</u> TAATCTGTATGCCGTTTAATTA GCTGA | PlcI / PlcDI |
| pNZ-F | TGTCGATAACGCGAGCATAA | |
| pNZ-R | CAAAGCAACACGTGCTGTAA | |
| PCR fragment | Description | |
| Plc-Clust | 3,172-bp fragment external to Plc cluster | |
| PlcADITEB | 2,908-bp <i>NcoI/XbaI</i> fragment containing genes <i>plcA</i> , <i>plcD</i> , <i>plcI</i> , <i>plcT</i> , <i>plcE</i> and <i>plcB</i> | |
| PlcD | 495-bp <i>NcoI/XbaI</i> fragment containing gene <i>plcD</i> | |
| PlcI | 204-bp <i>NcoI/XbaI</i> fragment containing gene <i>plcI</i> | |
| PlcDI | 662-bp <i>NcoI/XbaI</i> fragment containing genes <i>plcD</i> and <i>plcI</i> | |
| Plasmid | Description | |
| pNZ8048 | Cm ^r ; inducible expression vector carrying the <i>nisA</i> promoter (38) | |
| PNZPlc | pNZ8048 derivative containing PlcADITEB | |
| PNZPlcD | pNZ8048 derivative containing PlcD | |
| PNZPlcI | pNZ8048 derivative containing PlcI | |
| PNZPlcDI | pNZ8048 derivative containing PlcDI | |

607
608
609
610
611
612


^a Cleavage site for restriction enzymes is underlined in the primers.

613 Figure 1. A) Sequence alignment of all the members of subgroup II circular bacteriocins with plantaricyclin A, using MUSCLE (39). Conserved.
614 Conservative and semiconservative substitutions are indicated by asterisks, colons, and semicolons, respectively. Bold letters determine the
615 leader sequence. B) Schematic plantaricyclin A mature peptide.
616
617
618



639
640
641
642
643
644

Figure 2. Schematic representation of the gene clusters involved in the production of the circular bacteriocins gassericin A (34), acidocin B (17) and plantaricyclin A. The known or putative biochemical function or properties are denoted by color, as indicated in the key.



645
646
647
648
649
650
651
652
653
654
655
656
657
658
659




Figure 3. A) Antimicrobial activity of the CFS of *Lb. plantarum* NI326 and nisin A-induced *L. lactis* NZ9000 pNZPlc against *A. acidoterrestris* sp1. B) Antimicrobial activity of the CFS of *Lb. plantarum* NI326 against cultures of *L. lactis* NZ9000 pNZ8048, *L. lactis* NZ9000 pNZPlcD, *L. lactis* NZ9000 pNZPlcI and *L. lactis* NZ9000 pNZPlcDI un-induced (-) or induced (+) with nisin A.

Figure 4. MALDI TOF Mass spectrometry analysis of the purified plantaricyclin A produced by A) *L. lactis* pNZPlca; and B) *Lb. plantarum* NI326

